CCR6 regulates CD4+ T-cell-mediated acute graft-versus-host disease responses.

We studied the role of chemokine receptor CCR6 in acute graft-versus-host disease (GvHD), a pathology in which activated, host antigen-specific donor T cells selectively damage tissues such as skin, liver, and gut. GvHD incidence was reduced in major histocompatibility complex (MHC) class II-mismatched recipients of CD4+ T cells from CCR6-deficient donors. In MHC-matched/minor histocompatibility antigen-mismatched recipients of CD4+CD45RB(high) T cells from CCR6-deficient donors, infiltration of CD45+ and CD4+ cells to skin and gut, as well as lesion onset, were significantly delayed, and pathologic symptoms were milder. Consistent with this, in skin and gut of recipients of naive T cells from CCR6-deficient donors we observed lower levels of interferon gamma (IFN-gamma), interleukin 10 (IL-10), and the chemokines that control activated T-cell homing. We suggest a role for CCR6 in recruiting alloreactive CD4+ T cells to target tissues and identify CCR6 as a potential therapeutic target for GvHD.

[1]  M. Fishbein,et al.  Chemokine Monokine Induced by IFN-γ/CXC Chemokine Ligand 9 Stimulates T Lymphocyte Proliferation and Effector Cytokine Production1 , 2004, The Journal of Immunology.

[2]  J. Flores,et al.  CCR6 has a non‐redundant role in the development of inflammatory bowel disease , 2003, European journal of immunology.

[3]  J. Van Damme,et al.  The CC chemokine CCL20 and its receptor CCR6. , 2003, Cytokine & growth factor reviews.

[4]  S. Clouthier,et al.  Role of CXCR3-induced donor T-cell migration in acute GVHD. , 2003, Experimental hematology.

[5]  D. Danilenko,et al.  The role of interferon‐γ, nitric oxide and lipopolysaccharide in intestinal graft‐versus‐host disease developing in F1‐hybrid mice , 2003 .

[6]  M. Suematsu,et al.  Peyer's patch is the essential site in initiating murine acute and lethal graft-versus-host reaction , 2003, Nature Immunology.

[7]  S. Fujita,et al.  Antagonist of Secondary Lymphoid-Tissue Chemokine (CCR Ligand 21) Prevents the Development of Chronic Graft-Versus-Host Disease in Mice1 , 2003, The Journal of Immunology.

[8]  L. Mayer,et al.  Colonic epithelial cells are a major site of macrophage inflammatory protein 3α (MIP-3α) production in normal colon and inflammatory bowel disease , 2002, Gut.

[9]  C. Thoburn,et al.  Cytokine and chemokine profiles in autologous graft-versus-host disease (GVHD): interleukin 10 and interferon gamma may be critical mediators for the development of autologous GVHD. , 2002, Blood.

[10]  Derek D. Yang,et al.  Accelerated Onset and Increased Severity of Acute Graft-Versus-Host Disease Following Adoptive Transfer of DR6-Deficient T Cells , 2002, The Journal of Immunology.

[11]  L. McCormick,et al.  Murine Sclerodermatous Graft-Versus-Host Disease, a Model for Human Scleroderma: Cutaneous Cytokines, Chemokines, and Immune Cell Activation1 , 2002, The Journal of Immunology.

[12]  H. Soto,et al.  CCL27–CCR10 interactions regulate T cell–mediated skin inflammation , 2002, Nature Medicine.

[13]  Lisa M. Ebert,et al.  Up-Regulation of CCR5 and CCR6 on Distinct Subpopulations of Antigen-Activated CD4+ T Lymphocytes1 , 2002, The Journal of Immunology.

[14]  R. Soiffer,et al.  The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. , 2001, Blood.

[15]  James J. Campbell,et al.  CC Chemokine Receptor (CCR)4 and the CCR10 Ligand Cutaneous T Cell–attracting Chemokine (CTACK) in Lymphocyte Trafficking to Inflamed Skin , 2001, The Journal of experimental medicine.

[16]  O. Yoshie,et al.  Proinflammatory cytokines induce liver and activation-regulated chemokine/macrophage inflammatory protein-3α/CCL20 in mucosal epithelial cells through NF-κB , 2001 .

[17]  J. Antin.  Acute graft-versus-host disease: inflammation run amok? , 2001 .

[18]  D. Snider,et al.  Early Intestinal Th1 Inflammation and Mucosal T Cell Recruitment During Acute Graft-Versus-Host Reaction1 , 2001, The Journal of Immunology.

[19]  M. Leach,et al.  Characterization of chemokines and chemokine receptors in two murine models of inflammatory bowel disease: IL‐10– / – mice and Rag‐2– / – mice reconstituted with CD4+CD45RBhigh T cells , 2001, European journal of immunology.

[20]  M. Kagnoff,et al.  Regulated MIP-3alpha/CCL20 production by human intestinal epithelium: mechanism for modulating mucosal immunity. , 2001, American journal of physiology. Gastrointestinal and liver physiology.

[21]  C. Martínez-A,et al.  CCR6-deficient mice have impaired leukocyte homeostasis and altered contact hypersensitivity and delayed-type hypersensitivity responses. , 2001, The Journal of clinical investigation.

[22]  T. Tezuka,et al.  Inducible expression of a CC chemokine liver- and activation-regulated chemokine (LARC)/macrophage inflammatory protein (MIP)-3 alpha/CCL20 by epidermal keratinocytes and its role in atopic dermatitis. , 2001, International immunology.

[23]  S. Caughman,et al.  Cutting Edge: C-C Chemokine Receptor 6 Is Essential for Arrest of a Subset of Memory T Cells on Activated Dermal Microvascular Endothelial Cells Under Physiologic Flow Conditions In Vitro , 2000, The Journal of Immunology.

[24]  J. Serody,et al.  T-lymphocyte production of macrophage inflammatory protein-1α is critical to the recruitment of CD8+ T cells to the liver, lung, and spleen during graft-versus-host disease , 2000 .

[25]  S. Targan,et al.  The Role of Thymus-Expressed Chemokine and Its Receptor CCR9 on Lymphocytes in the Regional Specialization of the Mucosal Immune System1 , 2000, The Journal of Immunology.

[26]  C. Caux,et al.  Macrophage Inflammatory Protein 3α Is Expressed at Inflamed Epithelial Surfaces and Is the Most Potent Chemokine Known in Attracting Langerhans Cell Precursors , 2000, The Journal of experimental medicine.

[27]  C. Caux,et al.  Up-Regulation of Macrophage Inflammatory Protein-3α/CCL20 and CC Chemokine Receptor 6 in Psoriasis1 , 2000, The Journal of Immunology.

[28]  H. Greenberg,et al.  CCR6 mediates dendritic cell localization, lymphocyte homeostasis, and immune responses in mucosal tissue. , 2000, Immunity.

[29]  A. Iwasaki,et al.  Localization of Distinct Peyer's Patch Dendritic Cell Subsets and Their Recruitment by Chemokines Macrophage Inflammatory Protein (Mip)-3α, Mip-3β, and Secondary Lymphoid Organ Chemokine , 2000, The Journal of experimental medicine.

[30]  F. Sallusto,et al.  Two subsets of memory T lymphocytes with distinct homing potentials and effector functions , 1999, Nature.

[31]  M. Shlomchik,et al.  Prevention of graft versus host disease by inactivation of host antigen-presenting cells. , 1999, Science.

[32]  K. Matsushima,et al.  Active participation of CCR5(+)CD8(+) T lymphocytes in the pathogenesis of liver injury in graft-versus-host disease. , 1999, The Journal of clinical investigation.

[33]  Y. Tanaka,et al.  Selective expression of liver and activation‐regulated chemokine (LARC) in intestinal epithelium in mice and humans , 1999, European journal of immunology.

[34]  R. Rabin,et al.  CC-Chemokine Receptor 6 Is Expressed on Diverse Memory Subsets of T Cells and Determines Responsiveness to Macrophage Inflammatory Protein 3α , 1999, The Journal of Immunology.

[35]  Á. Zaballos,et al.  Molecular cloning, functional characterization and mRNA expression analysis of the murine chemokine receptor CCR6 and its specific ligand MIP‐3α 1 , 1998 .

[36]  K. HayGlass,et al.  Murine graft-versus-host disease in an F1-hybrid model using IFN-gamma gene knockout donors. , 1998, Journal of immunology.

[37]  E. Butcher,et al.  Chemokines and the arrest of lymphocytes rolling under flow conditions. , 1998, Science.

[38]  M. Detmar,et al.  Murine psoriasis-like disorder induced by naive CD4+ T cells , 1997, Nature Medicine.

[39]  A. B. Lyons,et al.  Determination of lymphocyte division by flow cytometry. , 1994, Journal of immunological methods.

[40]  Russell Higuchi,et al.  Kinetic PCR Analysis: Real-time Monitoring of DNA Amplification Reactions , 1993, Bio/Technology.

[41]  R. Riblet,et al.  H-40, an antigen controlled by an Igh linked gene and recognized by cytotoxic T lymphocytes. I. Genetic analysis of H-40 and distribution of its product on B cell tumors , 1984, The Journal of experimental medicine.

[42]  Eric J Kunkel,et al.  Chemokines and the tissue-specific migration of lymphocytes. , 2002, Immunity.

[43]  A. Zlotnik,et al.  Recent advances in chemokines and chemokine receptors. , 1999, Critical reviews in immunology.

[44]  W. Krenger,et al.  Graft-versus-host disease and the Th1/Th2 paradigm , 1996, Immunologic research.